Skip to main content
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2003 Mar;79(929):147–150. doi: 10.1136/pmj.79.929.147

Introduction to health economics for the medical practitioner

D Kernick 1
PMCID: PMC1742631  PMID: 12697913

Abstract

Against a background of increasing demands on limited resources, health economics is exerting an influence on decision making at all levels of health care. Health economics seeks to facilitate decision making by offering an explicit decision making framework based on the principle of efficiency. It is not the only consideration but it is an important one and practitioners will need to have an understanding of its basic principles and how it can impact on clinical decision making. This article reviews some of the basic principles of health economics and in particular economic evaluation.

Full Text

The Full Text of this article is available as a PDF (83.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Kernick D. Costing interventions in primary care. Fam Pract. 2000 Feb;17(1):66–70. doi: 10.1093/fampra/17.1.66. [DOI] [PubMed] [Google Scholar]
  2. Mauskopf J. A., Paul J. E., Grant D. M., Stergachis A. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998 Mar;13(3):277–288. doi: 10.2165/00019053-199813030-00002. [DOI] [PubMed] [Google Scholar]
  3. Pharoah P. D., Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ. 1996 Jun 8;312(7044):1443–1448. doi: 10.1136/bmj.312.7044.1443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Pickin D. M., McCabe C. J., Ramsay L. E., Payne N., Haq I. U., Yeo W. W., Jackson P. R. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart. 1999 Sep;82(3):325–332. doi: 10.1136/hrt.82.3.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Robinson R. Cost-benefit analysis. BMJ. 1993 Oct 9;307(6909):924–926. doi: 10.1136/bmj.307.6909.924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Robinson R. Cost-effectiveness analysis. BMJ. 1993 Sep 25;307(6907):793–795. doi: 10.1136/bmj.307.6907.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Robinson R. Cost-utility analysis. BMJ. 1993 Oct 2;307(6908):859–862. doi: 10.1136/bmj.307.6908.859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Torgerson D. J., Spencer A. Marginal costs and benefits. BMJ. 1996 Jan 6;312(7022):35–36. doi: 10.1136/bmj.312.7022.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Wells N. E., Steiner T. J. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics. 2000 Dec;18(6):557–566. doi: 10.2165/00019053-200018060-00003. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES